Journal List > Lab Med Online > v.3(4) > 1057213

Park, Kim, and Kim: Evaluation of the Performance of an Adiponectin ELISA-based Test and Establishing Serum Adiponectin Reference Intervals for Korean Population

Abstract

Background

Adiponectin is a plasma protein secreted by adipose tissues and low serum adiponectin concentration has been reported to be associated with insulin resistance and metabolic syndrome (MS). We evaluated the performance of an ELISA-based assay for measuring serum adiponectin levels and established reference intervals of adiponectin for Korean population.

Methods

Laboratory performance, including precision and linearity, of the AdipoMark Human Adiponectin ELISA kit (Mesdia Co., Korea) was assessed. Reference intervals of adiponectin concentration were determined after evaluation of 1200 subjects with no history of MS. Adiponectin was also measured in 100 patients with MS.

Results

The mean concentrations of serum samples tested for precision evaluation were 6.66, 12.61, and 23.42 µg/mL: the ELISA showed total imprecision of 13.6%, 9.3%, and 10.5% CV for the respective concentrations. The assay demonstrated linear responses in the range of 1.8-29.9 µg/mL serum adiponectin levels. The 95% reference intervals for Korean population were 3.6-19.2 µg/mL for men and 4.5-34.2 µg/mL for women. ROC-area under the curve values of adiponectin for the diagnosis of MS were 0.85 for men and 0.83 for women. Low adiponectin level was independently associated with MS in the multivariate analysis.

Conclusions

The adiponectin quantitation assay evaluated in this study showed acceptable laboratory and clinical performances in an ELISA platform. To meet the ever-increasing demand for a reliable assay for measuring adiponectin levels in the study of various metabolic diseases, this assay could be further improved by the automation of the platform.

Figures and Tables

Fig. 1
Determination of the linear relationship between the serum adiponectin levels by using AdipoMark Human Adiponectin ELISA kit. Dashed line indicates polynomial fit.
lmo-3-242-g001
Fig. 2
Distribution of serum adiponectin levels according to the age and sex of the subjects without metabolic syndrome. Serum adiponectin levels were higher in women than in men. Age-related variation in adiponectin levels was only observed in female subjects. P-values were calculated by Mann Whitney U test or Kruskal-Wallis test. The upper and lower ends of the boxes and box inner lines correspond to the upper and lower quartiles and median values, respectively. Whiskers denote the minimum and maximum values, and the circles indicate individual values.
lmo-3-242-g002
Table 1
Precision performance of the AdipoMark ELISA for measuring serum adiponectin levels during a 10-day evaluation period
lmo-3-242-i001

Abbreviations: ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; CV, coefficient of variation.

Table 2
Characteristics of Korean subjects (N=1,200) for the establishment of reference intervals
lmo-3-242-i002

*N=120 for the respective age and sex groups; Men vs. women (P-values were calculated by Mann Whitney U test.); P-value for the difference among the age groups was calculated by Kruskal-Wallis test with Bonferroni correction to compensate alpha-statistical error from multiple comparisons.

Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TG, triglyceride; HDL, high-density lipoprotein cholesterol.

Table 3
Reference intervals of serum adiponectin levels in the groups classified according to age and sex
lmo-3-242-i003

*90% CI for each age group and 95% CI for the total age groups for men and women.

Abbreviation: CI, confidence interval.

Table 4
Correlation between serum adiponectin levels (µg/mL) and other variables in normal Korean subjects (N=1,200) with no history of metabolic syndrome*
lmo-3-242-i004

*Bold letters imply statistically significant results.

Abbreviations: CI, confidence interval; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TG, triglyceride; HDL, high-density lipoprotein cholesterol.

Table 5
Results of the multivariate analysis using binary logistic regression with metabolic syndrome as a dependent variable and other factors as predictors in patients with metabolic syndrome (N=100) and healthy subjects (N=1,200)
lmo-3-242-i005

*Age, diastolic blood pressure, and waist circumference did not show a statistically significant association with the presence of metabolic syndrome in the multivariate analysis.

Abbreviations: CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglyceride; HDL, high-density lipoprotein cholesterol.

Notes

This article is available from http://www.labmedonline.org

References

1. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996; 221:286–289.
crossref
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257:79–83.
crossref
3. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100:2473–2476.
4. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000; 32:47–50.
crossref
5. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103:1057–1063.
crossref
6. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20:1595–1599.
crossref
7. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001; 86:3815–3819.
crossref
8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86:1930–1935.
crossref
9. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001; 50:1126–1133.
crossref
10. Rasmussen-Torvik LJ, Wassel CL, Ding J, Carr J, Cushman M, Jenny N, et al. Associations of body mass index and insulin resistance with leptin, adiponectin, and the leptin-to-adiponectin ratio across ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Ann Epidemiol. 2012; 22:705–709.
crossref
11. Liu Q, Yuan B, Lo KA, Patterson HC, Sun Y, Lodish HF. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc Natl Acad Sci U S A. 2012; 109:14568–14573.
crossref
12. Behnes M, Brueckmann M, Lang S, Putensen C, Saur J, Borggrefe M, et al. Alterations of adiponectin in the course of inflammation and severe sepsis. Shock. 2012; 38:243–248.
crossref
13. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012; 33:547–594.
crossref
14. Martos-Moreno GÁ, Burgos-Ramos E, Canelles S, Argente J, Barrios V. Evaluation of a multiplex assay for adipokine concentrations in obese children. Clin Chem Lab Med. 2010; 48:1439–1446.
crossref
15. Loo BM, Marniemi J, Jula A. Evaluation of multiplex immunoassays, used for determination of adiponectin, resistin, leptin, and ghrelin from human blood samples, in comparison to ELISA assays. Scand J Clin Lab Invest. 2011; 71:221–226.
crossref
16. Cangemi G, Di Iorgi N, Barco S, Reggiardo G, Maghnie M, Melioli G. Plasma total adiponectin levels in pediatrics: reference intervals calculated as a continuous variable of age. Clin Biochem. 2012; 45:1703–1705.
crossref
17. Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab. 2003; 88:2838–2843.
crossref
18. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma adiponectin. Clin Chem Lab Med. 2006; 44:1264–1268.
crossref
19. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003; 49:650–652.
crossref
20. Wildman RP, Wang D, Fernandez I, Mancuso P, Santoro N, Scherer PE, et al. Associations of testosterone and sex hormone binding globulin with adipose tissue hormones in midlife women. Obesity (Silver Spring). 2013.
crossref
21. Riestra P, García-Anguita A, Lasunción MA, Cano B, de Oya M, Garcés C. Relationship of adiponectin with metabolic syndrome components in pubertal children. Atherosclerosis. 2011; 216:467–470.
crossref
22. Yoon SJ, Lee HS, Lee SW, Yun JE, Kim SY, Cho ER, et al. The association between adiponectin and diabetes in the Korean population. Metabolism. 2008; 57:853–857.
crossref
23. Kotani K, Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general Japanese population. Korean J Lab Med. 2011; 31:162–166.
crossref
TOOLS
Similar articles